Accepted Abstracts: Surgery Curr Res
Malignant Hyperthermia (MH) is a pharamacogenetic disorder of skeletal muscle cells. At risk patients (MHS) would show potentially fatal hypermetabolic reaction in response to volatile anesthetic, and/or succinylcholine. This update explores the epidemiology of MH, discusses the role of calcium and intracellular proteins involved in the MH crisis, explains clinical characteristics based on recent literature, and describes the latest findings in genetic, and physiologic diagnostic testing of this disorder. In addition, this update will explore other related myopathies, such as central core disease, and an anesthetic approach for these patients are discussed in details. The author will share her latest research with regards to clinical epidemiology, as well as genetics of MH.
Sheila Riazi has completed her MSc in molecular biology at University of Toronto. Following completion of her residency in Anesthesia at University of Toronto, she completed her fellowship in regional anesthesia. She is currently a staff anesthesiologist at Toronto Western Hospital, and she is also the director of the only Canadian center for malignant hyperthermia diagnosis, and research. She is an affiliate scientist at Toronto General Research Institute. Her research focus is both in clinical and genetic aspects of malignant hyperthermia.